Emerging drug modalities targeting HER2

HER-2 is overexpressed in 20% of breast cancers, and since breast cancer has the highest prevalence worldwide, finding drugs to target HER2 is of paramount importance. This report aims to shed light on the emerging HER2-targeting drug modalities and highlight some of the most interesting molecular designs associated with them.

In this report you will find:

  • HER-2 targeting drugs in preclinical and Phase I development including ADCs, bispecifics, CAR therapies and cancer vaccines.
  • The most fascinating HER2 drugs in development along with their efficacy and toxicity results
  • An overview of the overall HER2 drug landscape

Do you have a future market research project that you’d like to discuss with us?